(Q44520576)

3 December 2017

title

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype (English)

1 reference

3 December 2017

1 reference

1 reference

3

1 reference

3 December 2017

Hajo J Flink

1

1 reference

3 December 2017

Monika van Zonneveld

2

1 reference

3 December 2017

Robert A de Man

4

1 reference

3 December 2017

Solko W Schalm

5

1 reference

3 December 2017

Harry L A Janssen

6

1 reference

3 December 2017

HBV 99-01 Study Group

7

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

The American Journal of Gastroenterology

3 December 2017

published in

1 reference

3 December 2017

volume

101

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

297-303

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

3 December 2017

1 reference

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Clinical significance of hepatitis B virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Hepatitis B genotypes and the response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00418.X

10.1111/J.1572-0241.2006.00418.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference